<DOC>
	<DOCNO>NCT02931110</DOCNO>
	<brief_summary>This clinical trial Phase 1 , open-label , sequential-group , dose-escalation ( Part 1 ) cohort-expansion study ( Part 2 ) evaluate safety , pharmacokinetics , pharmacodynamics , antitumor activity CBL0137 . The study evaluate CBL0137 administer IV weekly Days 1 8 repeat 21 day treatment cycle subject previously treat hematological malignancy .</brief_summary>
	<brief_title>Study IV CBL0137 Previously Treated Hematological Subjects</brief_title>
	<detailed_description>Part 1 study evaluate safety pharmacology range CBL0137 dose administer IV subject previously treat lymphoma , include diffuse large B-cell lymphoma ( DLBCL ) , follicular lymphoma ( FL ) , mantle cell lymphoma ( MCL ) , Hodgkin lymphoma ( HL ) . Part 2 study provide cohort expansion explore safety , pharmacology , clinical activity CBL0137 monotherapy subject specific previously treat hematological cancer , include DLBCL , FL , MCL , HL , chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , acute lymphoblastic leukemia ( ALL ) , acute myeloid leukemia ( AML ) , multiple myeloma ( MM ) .</detailed_description>
	<criteria>Presence active hematological malignancy : Part 1 ( Dose Escalation ) : Diagnosis Bcell DLBCL , FL , MCL , HL , document medical record . Part 2 ( Cohort Expansion ) : Diagnosis DLBCL , FL , MCL , HL , CLL/SLL , ALL , MM , AML document medical record . Requirement therapy hematological malignancy due diseaserelated symptom , lymphadenopathy , organomegaly , extranodal organ involvement , progressive disease . Hematological malignancy previously treat , relapse progress prior therapy , limited potential benefit currently available therapy , include hematopoietic stem cell transplantation . Presence measurable disease : For subject DLBCL , FL , MCL , HL , CLL/SLL : presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy ( define presence ≥1 lesion measure ≥2.0 cm long dimension [ LD ] ≥1.0 cm long perpendicular dimension [ LPD ] assess compute tomography [ CT ] ) . For subject MM , measurable disease serum monoclonal immunoglobulin protein ( Mprotein ) ≥1 g/dL , urine Mprotein protein ≥200 mg/24 hour , involve serum free light chain ( SFLC ) ≥10 mg/dL . For subject ALL AML , presence &gt; 5 % blast bone marrow ( base bone marrow aspirate/biopsy sample ≥200 nucleate cell presence bone marrow spicule ) and/or &gt; 1 x 109/L blast peripheral blood ( restriction peripheral blast count subject AML must &lt; 50 x 109/L prior start study therapy ) . Rapidly progressive , clinically unstable central nervous system hematological malignancy . Note : Central nervous system evaluation require subject know suspected central nervous system malignancy . Significant cardiovascular disease , include myocardial infarction , arterial thromboembolism , cerebrovascular thromboembolism , within 6 month prior start study therapy ; symptomatic dysrhythmias unstable dysrhythmias require medical therapy ; angina require therapy ; symptomatic peripheral vascular disease ; New York Heart Association Class 3 4 congestive heart failure ; uncontrolled Grade ≥3 hypertension ( diastolic blood pressure ≥100 mmHg systolic blood pressure ≥160 mmHg ) despite antihypertensive therapy ; history congenital prolong QT syndrome . Significant screen ECG abnormality , include unstable cardiac arrhythmia require medication , atrial fibrillation/flutter , leave bundlebranch block , 2nddegree atrioventricular ( AV ) block type II , 3rd degree AV block , Grade ≥2 bradycardia , QT correct heart rate ( QTc ) &gt; 450 msec ( men ) &gt; 470 msec ( woman ) . Ongoing risk bleed due active peptic ulcer disease bleed diathesis requirement systemic anticoagulation unfractionated heparin , lowmolecularweight heparin heparin fraction ( eg , enoxaparin , dalteparin , fondaparinux ) oral anticoagulant ( eg , apixaban , rivaroxaban , dabigatran etexilate , warfarin ) . Note : Use heparin thrombolytic agent local maintenance clearance central venous catheter permit . Evidence ongoing systemic bacterial , fungal , viral infection ( include upper respiratory tract infection ) time start study therapy . Note : Subjects localize fungal infection skin nail eligible . Please speak Investigator complete Inclusion/Exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diffuse large B-cell lymphoma ( DLBCL )</keyword>
	<keyword>follicular lymphoma ( FL )</keyword>
	<keyword>mantle cell lymphoma ( MCL )</keyword>
	<keyword>Hodgkin lymphoma ( HL )</keyword>
</DOC>